Inhibition of stat3 activity delays obesity-Induced thyroid carcinogenesis in a mouse model

Endocrine-Related Cancer

Volumn 23, Issue 1, 2016, Pages 53-63

  Park, Jeong Won ^a   Han, Cho Rong ^a   Zhao, Li ^a   Willingham, Mark C ^a   Cheng, Sheue Yann ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

JAK2 STAT3 signaling; Obesity; Preclinical mouse model; Pten deficiency; STAT3 inhibitor; Thyroid cancer; Thyroid hormone receptor mutant

Indexed keywords

4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; GELATINASE A; JANUS KINASE 2; LEPTIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; RETINOBLASTOMA PROTEIN; STAT3 PROTEIN; THYROTROPIN; VIMENTIN; AMINOSALICYLIC ACID DERIVATIVE; BENZENESULFONIC ACID DERIVATIVE; PTEN PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE; THYROID HORMONE RECEPTOR BETA;

ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MOUSE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CANCER; THYROID CARCINOGENESIS; THYROTROPIN BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; CELL PROLIFERATION; COMPLICATION; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; GENETICS; LIPID DIET; METABOLISM; MORTALITY; PATHOLOGY; THYROID GLAND; THYROID NEOPLASMS; TRANSGENIC MOUSE;

AMINOSALICYLIC ACIDS; ANIMALS; BENZENESULFONATES; CARCINOGENESIS; CELL PROLIFERATION; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; MICE; MICE, TRANSGENIC; OBESITY; PTEN PHOSPHOHYDROLASE; STAT3 TRANSCRIPTION FACTOR; THYROID GLAND; THYROID HORMONE RECEPTORS BETA; THYROID NEOPLASMS;

EID: 84953449453     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0417     Document Type: Article

References (48)

1. Ai T, Wang Z, Zhang M, Zhang L, Wang N, LiW Song L, 2012 Expression and prognostic relevance of STAT3 and cyclin D1 in non-small cell lung cancer. International Journal of Biological Markers 27 e132-e138. (doi:10. 5301/JBM.2012.9146).
2. Akinci M, Kosova F, Cetin B, Aslan S, Ari Z & Cetin A 2009 Leptin levels in thyroid cancer. Asian Journal of Surgery/Asian Surgical Association 32 216-223. (doi:10.1016/S1015-9584(09)60397-3).
3. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A & Frank DA 2005 Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Research 65 5054-5062. (doi:10.1158/0008-5472.CAN-04-4281).
4. Aschebrook-Kilfoy B, Sabra MM, Brenner A, Moore SC, Ron E, Schatzkin A, Hollenbeck A & Ward MH 2011 Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health Study. Thyroid 21 957-963. (doi:10.1089/thy.2010.0396).
5. Bowman T, Garcia R, Turkson J & Jove R 2000 STATs in oncogenesis. Oncogene 19 2474-2488. (doi:10.1038/sj.onc.1203527).
6. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C & Darnell JE Jr 1999 Stat3 as an oncogene. Cell 98 295-303. (doi:10. 1016/S0092-8674(00)81959-5).
7. Cheng SP, Chi CW, Tzen CY, Yang TL, Lee JJ, Liu TP & Liu CL 2010 Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery 147 847-853. (doi:10.1016/j.surg.2009.11.004).
8. Deng J, Hua K, Caveney EJ, Takahashi N & Harp JB 2006 Protein inhibitor of activated STAT3 inhibits adipogenic gene expression. Biochemical and Biophysical Research Communications 339 923-931. (doi:10.1016/j.bbrc. 2005.10.217).
9. Dong W, Cui J, Tian X, He L, Wang Z, Zhang P & Zhang H 2014 Aberrant sonic hedgehog signaling pathway and STAT3 activation in papillary thyroid cancer. International Journal of Clinical and Experimental Medicine 7 1786-1793.
10. Dutzmann J, Daniel JM, Bauersachs J, Hilfiker-Kleiner D & Sedding DG 2015 Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovascular Research 106 365-374. (doi:10.1093/cvr/cvv103).
11. Fan YL & Li XQ 2015 Expression of leptin and its receptor in thyroid carcinoma: distinctive prognostic significance in different subtypes. Clinical Endocrinology 83 261-267. (doi:10.1111/cen.12598).
12. Furumoto H, Ying H, Chandramouli GV, Zhao L, Walker RL, Meltzer PS, Willingham MC & Cheng SY ,2005 An unliganded thyroid hormone b receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Molecular and Cellular Biology 25 124-135. (doi:10.1128/MCB.25.1.124-135.2005).
13. Guarino M, 2010 Src signaling in cancer invasion. Journal of Cellular Physiology 223 14-26. (doi:10.1002/jcp.22011).
14. Guigon CJ, Zhao L, Willingham MC & Cheng SY ,2009 PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene 28 509-517. (doi:10.1038/onc.2008.407).
15. Harp JB, Franklin D, Vanderpuije AA & Gimble JM 2001 Differential expression of signal transducers and activators of transcription during human adipogenesis. Biochemical and Biophysical Research Communications 281 907-912. (doi:10.1006/bbrc.2001.4460).
16. Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA et al. ,2012 A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clinical Cancer Research 18 3396-3406. (doi:10.1158/1078- 0432.CCR-11-2703).
17. Kim HJ, Kim NK, Choi JH, Sohn SY, Kim SW, Jin SM, Jang HW, Suh S, Min YK, Chung JH et al. ,2013a Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clinical Endocrinology 78 134-140. (doi:10.1111/j.1365-2265.2012. 04506.x).
18. Kim WG, Park JW, Willingham MC & Cheng SY ,2013b Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model. Endocrinology 154 2936-2947. (doi:10.1210/en.2013-1128).
19. Kim JE, Patel M, Ruzevick J, Jackson CM& Lim M 2014 STAT3 activation in glioblastoma: biochemical and therapeutic implications. Cancers 6 376-395. (doi:10.3390/cancers6010376).
20. Kitahara CM, Platz EA, Freeman LE, Hsing AW, LinetMS, Park Y, Schairer C, Schatzkin A, Shikany JM & Berrington de Gonzalez A ,2011 Obesity and thyroid cancer risk among US men and women: A pooled analysis of fiveprospective studies. Cancer Epidemiology, Biomarkers & Prevention 20 464-472. (doi:10.1158/1055-9965.EPI-10-1220).
21. Lamouille S, Xu J & Derynck R, 2014 Molecular mechanisms of epithelialmesenchymal transition. Nature Reviews. Molecular Cell Biology 15 178-196. (doi:10.1038/nrm3758).
22. Lee MH, Lee JU, Joung KH, Kim YK, Ryu MJ, Lee SE, Kim SJ, Chung HK, Choi MJ, Chang JY et al. 2015 Thyroid dysfunction associated with follicular cell steatosis in obese male mice and humans. Endocrinology 156 1181-1193. (doi:10.1210/en.2014-1670).
23. Liu X, He Z, Li CH, Huang G, Ding C & Liu H, 2012 Correlation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancer. Pathology Oncology Research 18 17-23. (doi:10.1007/s12253-011- 9410-y).
24. Masuda M, Ruan HY, Ito A, Nakashima T, Toh S, Wakasaki T, Yasumatsu R, Kutratomi Y, Komune S & Weinstein IB, 2007 Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma. Oral Oncology 43 785-790. (doi:10.1016/j.oraloncology. 2006.10.007).
25. Meinhold CL, Ron E, Schonfeld SJ, Alexander BH, Freedman DM, Linet MS & Berrington de Gonzalez A, 2010 Nonradiation risk factors for thyroid cancer in the US Radiologic Technologists Study. American Journal of Epidemiology 171 242-252. (doi:10.1093/aje/kwp354).
26. Min H &Wei-hong Z, 2009 Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma. Journal of Obstetrics and Gynaecology Research 35 918-925. (doi:10.1111/j.1447- 0756.2009.01045.x).
27. Nevins JR 1992 E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science 258 424-429. (doi:10.1126/science. 1411535).
28. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB & Laurence A 2015 The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annual Review of Medicine 66 311-328. (doi:10.1146/annurev-med-051113-024537).
29. Pappa T & Alevizaki M 2014 Obesity and thyroid cancer: A clinical update. Thyroid 24 190-199. (doi:10.1089/thy.2013.0232).
30. Rehem RA, Elwafa WA, Elwafa RA & Abdel-Aziz TE 2014 Study of serum leptin in well-differentiated thyroid carcinoma: correlation with patient and tumor characteristics. World Journal of Surgery 38 2621-2627. (doi:10.1007/s00268-014-2634-8).
31. Renehan AG, Tyson M, Egger M, Heller RF & Zwahlen M 2008 Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 371 569-578. (doi:10.1016/S0140-6736(08)60269-X).
32. Sen N, Che X, Rajamani J, Zerboni L, Sung P, Ptacek J & Arvin AM 2012 Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. PNAS 109 600-605. (doi:10.1073/pnas.1114232109).
33. Sheen-Chen SM, Huang CC, Tang RP, Chou FF & Eng HL 2008 Prognostic value of signal transducers and activators of transcription 3 in breast cancer. Cancer Epidemiology, Biomarkers & Prevention 17 2286-2290. (doi:10.1158/1055-9965.EPI-08-0089).
34. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ et al. 2007 Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. PNAS 104 7391-7396. (doi:10.1073/pnas.0609757104).
35. Simard EP, Ward EM, Siegel R & Jemal A, 2012 Cancers with increasing incidence trends in the United States: 1999 through 2008. CA: A Cancer Journal for Clinicians 62 118-128. (doi:10.3322/caac.20141).
36. Stephens JM, Morrison RF & Pilch PF 1996 The expression and regulation of STATs during 3T3-L1 adipocyte differentiation. Journal of Biological Chemistry 271 10441-10444. (doi:10.1074/jbc.271.18.10441).
37. Tania M, Khan MA & Fu J, 2014 Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biology 35 7335-7342. (doi:10.1007/s13277-014-2163-y).
38. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M et al. 2009 Phase I clinical trials in 56 patients with thyroid cancer: The M D Anderson Cancer Center experience. Journal of Clinical Endocrinology and Metabolism 94 4423-4432. (doi:10.1210/jc.2009-0743).
39. Wang D, Zhou Y, Lei W, Zhang K, Shi J, Hu Y, Shu G & Song J 2010 Signal transducer and activator of transcription 3 (STAT3) regulates adipocyte differentiation via peroxisome-proliferator-activated receptor gamma (PPARg). Biology of the Cell/Under the Auspices of the European Cell Biology Organization 102- 112. (doi:10.1042/BC20090070).
40. WeiD, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL et al. 2003 Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22 319-329. (doi:10.1038/sj.onc.1206122).
41. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R & Huang S 2004 Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23 3550-3560. (doi:10.1038/sj.onc.1207383).
42. Xiong H, Hong J, Du W, Lin YW, Ren LL, Wang YC, Su WY, Wang JL, Cui Y, Wang ZH et al. 2012 Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. Journal of Biological Chemistry 287 5819-5832. (doi:10.1074/jbc.M111.295964).
43. Yadav A, Kumar B, Datta J, Teknos TN & Kumar P 2011 IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Molecular Cancer Research 9 1658-1667. (doi:10.1158/1541-7786.MCR-11-0271).
44. Yakata Y, Nakayama T, Yoshizaki A, Kusaba T, Inoue K & Sekine I 2007 Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. International Journal of Oncology 30 437-442.
45. Zhang J, Gill A, Atmore B, Johns A, Delbridge L, Lai R & McMullen T 2011 Upregulation of the signal transducers and activators of transcription 3 (STAT3) pathway in lymphatic metastases of papillary thyroid cancer. International Journal of Clinical and Experimental Pathology 4 356-362.
46. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, Paladino D, Zhao J, Chen Y, Gunning PT et al. 2012 Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. PNAS 109 9623-9628. (doi:10.1073/pnas. 1121606109).
47. Zhao ZG, Guo XG, Ba CX, Wang W, Yang YY, Wang J & Cao HY 2012 Overweight, obesity and thyroid cancer risk: A meta-analysis of cohort studies. Journal of International Medical Research 40 2041-2050. (doi:10.1177/030006051204000601).
48. Zhu X, Zhao L, Park JW, Willingham MC & Cheng SY 2014 Synergistic signaling of KRAS and thyroid hormone receptor b mutants promotes undifferentiated thyroid cancer through MYC up-regulation. Neoplasia 16 757-769. (doi:10.1016/j.neo.2014.08.003).